Abstract: Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: A bipolar plate for an electrochemical system. The bipolar plate comprising a first individual plate and a second individual plate which are joined together. Each individual plate comprising: an electrochemically active region, an outer edge, and a perimeter sealing element. The outer edge region spans between the edge of the perimeter sealing element and the outer edge. Some emobidments of the outer edges protrude out of a plate plane defined by the bipolar plate. A plurality of stiffening structures stiffening the outer edge region of the bipolar plate.

Abstract: An IL-11 binding receptor capable of binding to IL-11 and inhibiting IL-11 mediated signalling is disclosed. Also disclosed are compositions comprising the IL-11 binding receptor and methods using the IL-11 binding receptor.

Abstract: Provided are antigen-binding molecules capable of binding to IL-11R?, and methods of medical treatment and prophylaxis using the same.

Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.

Abstract: Methods for the diagnosis, treatment and prophylaxis of fibrosis and/or angiogenesis, in particular in the eye, are disclosed. In particular embodiments, the methods employ antagonism of IL-11 mediated signalling and antagonism of angiogenesis. Also provided are combinations comprising an antagonist of IL-11 mediated signalling and an antagonist of an angiogenic factor.

Abstract: IL-11R? antibodies are disclosed. Also disclosed are compositions comprising the IL-11R? antibodies, and methods using the IL-11R? antibodies.

Abstract: IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.

Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.

Abstract: A separator plate arrangement for an electrochemical system, comprising a first metal sheet and a second metal sheet. The first metal sheet has a first circumferential sealing structure for sealing off an electrochemically active region, a first cutout arranged outside of the first circumferential sealing structure, and a first embossed structure arranged outside of the first circumferential sealing structure. The second metal sheet has a second circumferential sealing structure for sealing off an electrochemically active region, a second cutout arranged outside of the second circumferential sealing structure, and a second embossed structure arranged outside of the second circumferential sealing structure.

Abstract: Systems for reducing the decibel levels of sound originated external to a sports protective helmet may minimize deleterious effects to the hearing of the individual wearing the sports protective helmet. Through use of a sound reducing object, whether placed in the interior of the sports protective helmet or external to the sports protective helmet, decibel volumes may be reduced across key frequencies that reach human ears while still allowing a player to hear. The result is substantial reduction in hearing loss related to sporting activities.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.